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Background: We determined the prevalence of anti-nuclear autoantibodies (ANAs) in the German adult population
and examined the association between ANAs and cardiovascular and metabolic disorders.
Methods: We used data and blood samples from the pretest phases of the German National Cohort, obtained from
six of the 18 study centers (n = 1199). All centers applied standardized instruments including face-to-face interviews,
anthropometric measurements and collection of blood samples. Self-reported histories of diabetes mellitus, heart
attack and elevated blood cholesterol and/or lipids were recorded. Height, weight and blood pressure were measured.
ANAs were detected using a semi-automated system (AKLIDES®; Medipan GmbH, Dahlewitz, Germany). A positive ANA
was defined as a titer≥ 1:80. ANA were classified as weakly (1:80 or 1:160), moderately (1:320 or 1:640) or strongly
(≥1:1280) positive. Specific autoantibodies against nuclear antigens were detected with second-step assays according
to the ANA staining pattern. Associations between the assessed disorders and ANA positivity and pattern were
examined using sex and age-adjusted mixed-effects logistic regression models.
Results: Thirty-three percent (95% confidence interval; 31–36%) of the 1196 participants (measurements could not be
obtained from three samples) were ANA positive (titer≥ 1:80). The proportions of weakly, moderately and strongly
positive ANA were 29%, 3.3% and 1.3%, respectively. ANA positivity was more common among women than men
across all titers (χ2, p = 0.03). ANA positivity, even when stratified according to height of titer or immunofluorescent
pattern, was not associated with diabetes, elevated blood cholesterol and/or lipids, obesity or hypertension. Second-step
autoantibody assays were positive in 41 of the 83 samples (49%) tested, with anti-DFS70 (n= 13) and anti-dsDNA (n= 7)
being most frequent. These subgroups were too small to test for associations with the disorders assessed.
(Continued on next page)* Correspondence: manas.akmatov@twincore.de
†Equal contributors
1TWINCORE, Centre for Experimental and Clinical Infection Research,
Feodor-Lynen-Straße 7, 30625 Hannover, Germany
2Helmholtz Centre for Infection Research, Braunschweig, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Akmatov et al. Arthritis Research & Therapy  (2017) 19:127 Page 2 of 9(Continued from previous page)
Conclusions: The prevalence of ANA positivity in the German general population was similar to values reported from
other countries. Contrary to other studies, there was no association with selected self-reported and objectively
measured cardiovascular and metabolic variables.
Keywords: Anti-nuclear autoantibodies, Diabetes, German National Cohort, Hypertension, Metabolism, Obesity,
Population-based studyBackground
Anti-nuclear autoantibodies (ANAs) are immunoglobulins
commonly used as an initial test to screen for connective
tissue diseases such as systemic lupus erythematosus
(SLE), systemic sclerosis, polymyositis, dermatomyositis
or Sjögren’s syndrome (SjS) [1]. The ANA diagnostic is
a sensitive test to evaluate these diseases, particularly
SLE. However, the presence of ANAs is not specific for
any particular connective tissue disease and can be as-
sociated with various other conditions such as cancer,
chronic infections and cardiovascular diseases, and with
use of certain medications [2, 3]. Even all-cause mortal-
ity has been associated with a positive ANA test [4].
One possible explanation for this phenomenon is that
the presence of ANAs may reflect an increased baseline
level of general inflammation and/or autoimmunity that
is deleterious to the function of more than one organ.
Tests for ANAs can also be positive in healthy individuals,
particularly in low titers. For instance, a population-based
study in China reported that approximately 6% of healthy
individuals tested positive for ANA with a titer of 1:320
[5]. In a Mexican study, ANAs were detected in 35% of
healthy individuals (titer 1:40) [6]. A higher risk of ANA
positivity is associated with female sex [7] and increasing
age [5]. Evidence is emerging that associations may also
exist between ANA positivity and certain parameters of
cardiovascular and metabolic dysfunction. For instance,
high ANA titers have been associated with coronary
atherosclerosis [8], and individuals positive for ANA
were reported to be more likely to develop myocar-
dial infarction and peripheral vascular disease [9]. In
terms of metabolic endpoints, Gonzalez et al. [10] found
an inverse association between obesity and ANA positivity
in women (but none in men), and Heras et al. [11] ob-
served higher ANA positivity among individuals with type
1 diabetes than among nondiabetic individuals. To our
knowledge, there are no data derived from the German
general population on ANA prevalence or the association
between ANA positivity and cardiovascular and metabolic
disorders. The aims of the present study were therefore to
determine the prevalence of ANAs in a multicenter
population-based study in Germany and to examine their
association with selected cardiovascular and metabolic
disorders.Methods
Sampling
The German National Cohort (GNC, in German also
known as the NaKo Gesundheitsstudie) is a large-scale
multicenter population-based prospective cohort study
aiming to recruit 200,000 male and female participants
between 20 and 69 years of age in 18 study centers dis-
tributed across Germany [12]. Recruitment of partici-
pants for the main study started in 2014. For the present
study, we used data and blood samples from the first
and second pretest studies of the GNC conducted in
2011 and 2012, respectively, and covering six study cen-
ters (Augsburg, Bremen, Essen, Hamburg, Hannover and
Heidelberg). The aim of the pretest studies was to test
the feasibility of selected instruments. Population-based
sampling was used to recruit participants, and therefore
samples were drawn from population registries of the re-
spective municipalities. In addition, in two study centers
(Essen and Heidelberg), selected migrant populations were
recruited using register and community-based approaches
[13]. The latter included recruitment via social networks
(e.g., in groceries frequented by migrants, mosques or gen-
eral practitioners’ offices). The study population in Essen
comprised individuals of Turkish origin only; in Heidelberg,
in addition to nonmigrant individuals, recruitment included
the two largest migrant population groups—that is, individ-
uals of Turkish origin and ethnic German immigrants from
the former Soviet Union (FSU resettlers) [13]. In both study
centers, bilingual study documents (e.g., flyers, posters,
questionnaires, etc.) were offered.
The proportion of older individuals was oversampled
in that 26.7% were recruited in each of the three older
age groups (40–49, 50–59 and 60–69 years) and 10% in
each of the younger age groups (20–29 and 30–39
years). Individuals were contacted through land mail;
nonresponders received up to two reminders and up to
10 telephone calls (provided that telephone numbers
could be identified). Computer-assisted face-to-face in-
terviews were performed to collect sociodemographic
and health-related data in all study centers except Essen,
where a questionnaire was administered. Anthropomet-
ric measurements were obtained from all participants.
Finally, biologic specimens (e.g., blood, urine and stool
samples, nasal swabs) were collected.
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As part of the medical history, information on chronic
diseases and medical events relevant to the presented
study was collected by the questions “Have you ever been
diagnosed with … [diabetes mellitus, myocardial infarction,
elevated blood cholesterol and/or lipids] by a physician?”,
with separate “yes”, “no” and “I don’t know” options for
each item. Height and body weight were measured with the
SECA 285 measuring station (SECA, Hamburg, Germany).
Body mass index (BMI) was calculated using the formula
weight/height2 (kg/m2). BMI ≥ 25 kg/m2 and BMI ≥ 30 kg/
m2 were used to define overweight and obesity, respectively
[14]. Blood pressure was measured three times within a
15-minute period with an HEM 705 IT blood pressure
monitor (OMRON Healthcare Europe, the Netherlands),
except in Essen where it was measured only once. We cal-
culated the mean of the second and third measurements
and defined hypertension as a systolic or diastolic blood
pressure higher than 140 mmHg and/or 90 mmHg, re-
spectively [15]. The study center in Essen was excluded
from this analysis because only a single measurement was
available. Self-reported information on hypertension was
not used in our analysis.
ANA as exposure variable
First, we divided the participants into two groups; negative
and positive for ANA. A titer of at least 1:80 was used to
define positivity. Second, participants were divided into
four ANA subgroups: negative, weakly positive (titer 1:80
or 1:160), moderately positive (titer 1:320 or 1:640) and
strongly positive (titer ≥1:1280).
Laboratory analyses
ANAs were detected by indirect immunofluorescence on
HEp-2 cells. The assessment of autoantibody titers and
five main patterns (granular/fine granular, homogeneous/
homogeneous fine granular, nucleolar, centromer and other
patterns) was carried out with a semi-automated system
(AKLIDES®; Medipan GmbH, Dahlewitz, Germany) [16–
18] and confirmed by visual observation. Sera assessed as
positive (titer ≥ 1:80) were further analyzed by specific
second-step autoantibody assays according to the staining
pattern. The selection of the following confirmatory assays
was carried out according to test algorithms of routine
diagnostics. For sera with granular/fine granular pattern,
antibodies against Ro/SS-A, La/SS-B, U1-RNP and Sm
were determined by ELISAs (Orgentec Diagnostika GmbH,
Germany). Furthermore, immunodiffusion with extractable
nuclear antigen (Hiss diagnostics GmbH, Germany)
was applied. If homogeneous or homogeneous fine gra-
nular pattern occurred, ELISAs for the detection of
antibodies against dsDNA, histones and nucleosomes
(Seramun diagnostica GmbH, Germany) and Bioflash®
chemiluminescence assay for the determination of DFS-70antibodies (INOVA diagnostics Inc., USA) were per-
formed. If a nucleolar pattern was observed, the EURO-
LINE® Immunoblot (EUROIMMUN Medizinische
Labordiagnostika AG, Germany) for the detection of
PMScl and Scl-70 antibodies was carried out. Because anti-
centromere antibodies provide a specific pattern on HEp-2-
cells, no antigen-specific confirmatory assay was necessary.
Statistical analysis
Initially, we performed a descriptive analysis by study
center. The differences in sociodemographic variables
across the study centers were examined with the chi-square
test or Fisher’s exact test. Furthermore, we pooled the data
from all study centers and estimated the sex and age-
specific prevalence of ANAs. The differences in ANA posi-
tivity between sex and country of birth were tested with the
chi-square test or Fisher’s exact test. As a next step, we ap-
plied mixed-effects logistic regression analysis to examine
the association between ANA positivity and cardiovascular
and metabolic disorders. The models were adjusted for
sex and age; the study center was included as a random
effect. The procedure PROC GLIMMIX was used for
mixed-effects logistic regression analysis. For this analysis,
moderately and strongly positive samples were combined
into one category because the proportion of strongly
positive samples was very low to be analyzed separately.
The analysis was performed with the statistical program
SAS for Windows, version 9.2 (SAS Institute Inc., Cary,
NC, USA) and R Foundation for Statistical Computing
software (version 3.0.2).
Results
Description of the study population
Table 1 presents selected demographic and clinical data
and ANA positivity by study center and for the total study
population. The proportion of women was higher in all
study centers, with the greatest differences in Essen and
Heidelberg. The proportion of obese participants was twice
as high in Essen as in the other study centers. There were
apparent, albeit not statistically significant, differences
across centers in the proportions of self-reported heart at-
tacks (Fisher’s exact test, p = 0.18) or diabetes (χ2 = 5.129,
df = 5, p = 0.40; Fisher’s exact test, p = 0.19).
Sex and age-specific ANA prevalence rates
The proportion of participants with a positive ANA test
(titer ≥ 1:80) was 33.3% (95% confidence intervals: 30.7–
35.9%). There was a trend toward more frequent ANA
positivity with increasing age among women (χ2 = 6.983,
df = 4, p for trend = 0.09) but not men. With the excep-
tion of the age group 30–39, the proportion of ANA
positivity was higher among women than men in all age
groups, with the most significant difference in the age
group 50–59 (Fig. 1). There was no significant difference
















Male 48.2 45.2 39.1 47.9 47.2 38.9 43.8
Female 51.8 54.8 60.9 52.1 52.8 61.1 56.2
Median age (IQR) 55 (47–63) 54 (41–62) 41 (34–50) 48 (30–62) 52 (43–62) 45 (31–59) <0.0001b 49 (38–60)
Country of birth <0.0001
Germany 83.5 83.8 21.3 88.7 87.7 40.9 64.0
Other 16.5 16.3 78.7 11.3 12.3 59.1 36.0
BMI <0.0001
Underweight (<18.50 kg/m2) 0 1.2 0.4 1.7 2.8 2.6 1.3
Normal weight (18.50–24.99 kg/m2) 33.8 43.2 18.5 51.1 46.2 46.9 38.7
Overweight (25.00–29.99 kg/m2) 46.8 39.0 39.9 32.5 35.8 31.3 37.3
Obesity (≥30.00 kg/m2) 19.4 16.6 41.3 14.8 15.1 19.3 22.7
Heart attack 0.18
Yes 5.0 0.8 2.3 1.7 2.8 2.6 2.3
No 95.0 99.2 97.7 98.3 97.2 97.4 97.7
Diabetes 0.40
Yes 7.2 5.4 9.9 5.9 4.7 6.8 6.8
No 92.8 94.6 90.1 94.1 95.3 93.2 93.2
ANA positivity 0.742
Negative (<1:80) 67.6 63.9 66.8 65.1 71.7 68.8 66.7
Positive (≥1:80) 32.4 36.1 33.2 34.9 28.3 31.3 33.3
ANA positivity 0.157
Negative (<1:80) 67.6 63.9 66.8 65.1 71.7 68.8 66.7
Weakly positive (1:80 & 1:160) 25.2 29.0 29.6 32.4 26.4 25.5 28.6
Moderately positive (1:320 & 1:640) 3.6 5.8 2.5 1.3 1.9 4.7 3.3
Strongly positive (≥1:1280) 3.6 1.2 1.1 1.3 0 1.0 1.3
ANA anti-nuclear autoantibody, IQR interquartile range, BMI body mass index
aChi-square test or Fisher’s exact test for differences across study centers
bKruskal–Wallis test for differences across study centers
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ters (Table 1, χ2 = 2.727, df = 5, p = 0.742). Of the 1196
participants with available ANA results (measurements
could not be obtained from three samples), 342 (28.6%),
40 (3.3%) and 16 (1.3%) were classified as weakly, moder-
ately and strongly positive, respectively. The prevalence of
weakly, moderately and strongly positive ANA titers
was higher among women than men (Fig. 2a, χ2 = 8.859,
df = 3, p = 0.03). There were no differences in ANA
positivity between participants born in Germany and
abroad (Fig. 2b).
ANA staining patterns
The most frequent ANA staining patterns were granular/
fine granular pattern (74.1%), followed by homogeneous/homogeneous fine granular (19.2%) and nucleolar (2.6%)
(Fig. 3a). The granular/fine granular pattern predominated
in samples with weak ANA positivity (Fig. 3b). The
centromere pattern was only present among strongly
ANA-positive samples (Fig. 3b).Second-step autoantibody detection
The results of confirmatory testing for 19 specific autoanti-
bodies are presented in Table 2. Of the 10 (53%) detected
autoantibodies, anti-DFS70 (n = 13) and anti-dsDNA
(n = 7) were the most frequently detected. There was
a tendency for more frequent positivity for second-
step autoantibodies with increasing ANA titer (χ2 =
3.072, df = 1, n = 83, p for trend = 0.08).
Fig. 1 ANA positivity by sex and age groups. ANA positivity was defined as a titer≥ 1:80. Whiskers indicate 95% confidence intervals. *p = 0.003
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metabolic disorders
Table 3 presents age and sex-adjusted ORs for the car-
diovascular and metabolic parameters assessed. There
was no association between ANA positivity and the self-
reported (diabetes, elevated blood cholesterol/lipids) or
objectively measured (obesity, hypertension) parameters.
Likewise, there were no associations between ANA
staining patterns and these variables, even when only in-
dividuals with titers ≥ 1:80 were considered (data nota
Fig. 2 Proportion of weakly, moderately and strongly positive ANA titers b
1:320 or 1:640; strong, ≥1:1280). Difference in ANA positivity by sex was
ANA positivity by country of birth was not significant (χ2 = 1.121, df = 3,
anti-nuclear autoantibodyshown). An association with heart attack could not be
tested due to the low number of reported cases (Table 1).
Discussion
Using a semi-automated high-throughput system, we
determined the frequencies of ANAs in the German
general population at different titer cutoff point and
patterns and looked for associations with selected cardio-
vascular and metabolism-related diseases. The detected
prevalences were comparable with published values fromb
y sex (a) and by country of birth (b) (weak, 1:80 or 1:160; moderate,
significant (χ2 = 8.859, df = 3, p = 0.03). *p = 0.02. Difference in
p = 0.77). Whiskers indicate 95% confidence intervals. ANA
Fig. 3 ANA staining patterns. Frequencies of patterns across all samples (a) and according to degree of positivity (b) (weak, 1:80 or 1:160;
moderate, 1:320 or 1:640; strong, ≥1:1280). ANA anti-nuclear autoantibody
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tween ANAs at any titer or pattern and the cardiovascular
and metabolic diseases assessed.
Only a few studies on ANA prevalence have so far
been conducted among the general population [5, 6, 19].
None of them used population-based sampling as weTable 2 Proportion of positive results for specific auto-antibodies fro











Myositis blot 0 0
SSC blot 0 0
Rib-P 0 0
Jo-1 0 0




F-actin 0 0did. A Mexican study involving healthy individuals (blood
donors, health care workers and relatives of patients
with connective tissue disorders) demonstrated similar
prevalence rates; for example, an ANA positivity of
35% with a titer ≥ 1:40 [6]. Guo et al. [5] used a titer
cutoff point of 1:320 to determine ANA positivity amongm confirmatory assays (%)
Number and proportion of positive results
in samples with ANA titer (n (%))
r all antibodies (%) (N = 83) 1:80 and 1:160 1:320 and 1:640 ≥1:1280
3 (23) 6 (46) 4 (31)
2 (29) 5 (71) 0 (0)
0 (0) 2 (50) 2 (50)
1 (25) 3 (75) 0 (0)
0 (0) 4 (100) 0 (0)
0 (0) 0 (0) 2 (100)
0 (0) 0 (0) 2 (100)
0 (0) 2 (100) 0 (0)
0 (0) 0 (0) 2 (100)
0 (0) 1 (100) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
Table 3 Age and sex-adjusted odds ratios for the cardiovascular and metabolic disorders assessed (results of the four mixed-effects
logistic regression models)
Obesitya Diabetesb Hypertensiona Elevated blood cholesterol
and/or lipidsb
AOR (95% CI) p valuec AOR (95% CI) p valuec AOR (95% CI) p valuec AOR (95% CI) p valuec
ANA positivity 0.99 0.73 0.66 0.71
Negative (n = 756) Reference Reference Reference Reference
Weakly positive (n = 320) 0.98 (0.71–1.35) 0.86 (0.49–1.50) 0.72 (0.47–1.10) 1.13 (0.83–1.53)
Moderately or strongly positive (n = 53) 1.00 (0.50–1.97) 0.66 (0.19–2.28) 1.00 (0.45–2.23) 0.94 (0.50–1.77)
ANA anti-nuclear autoantibody, AOR adjusted odds ratio, BMI body mass index, CI confidence interval
aObjectively measured weight and height and blood pressure (see Methods). Obesity was defined as BMI ≥ 30 kg/m2. Hypertension was defined as a systolic or
diastolic blood pressure ≥ 140 mmHg and/or 90 mmHg, respectively
bSelf-reported information
cTests of fixed effects
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of participants were positive. This figure was comparable
with our study. Andersen-Ranberg et al. [20] examined
the prevalence of nonorgan-specific autoantibodies among
Danish healthy centenarians and observed a slightly higher
ANA prevalence (37%, titer ≥ 1:40) than in our study. The
international recommendation for the determination of
ANA indicates titers of 1:160 or above as positive [21], and
the European Autoimmunity Standardization Initiative
(EASI) recommends sera with titers of 1:80 as borderline
and with titers ≥ 1:160 to be considered positive [22]. The
aim of both initiatives was to improve the diagnostics of pa-
tients with systemic autoimmune rheumatic diseases, but
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ANA anti-nuclear autoantibody, BMI body mass indexgeneral population. Therefore, as suggested by the manu-
facturer of the HEp-2-cell assay, in our study we used a
titer ≥ 1:80 to define sera as positive. This cutoff point rep-
resents a sensitivity of 98.1% and a specificity of 91.2% of
the AKLIDES system for the detection of ANAs in 156
sera with defined antinuclear antibodies and 263 nonse-
lected blood donors [23]. Low ANA titers may not be of
clinical significance [1], but higher titers might predict the
development of autoimmune diseases such as SLE.
Arbuckle et al. [24] investigated the onset of ANAs before
diagnosis of SLE and observed that ANAs (with a dilution
of 1:120) were present in 78% of SLE patients before
diagnosis. We found about 3.3% and 1.3% of our partici-
pants to have moderately (titer of 1:320 or 1:640) andNAs and various cardiovascular and metabolic disorders and





arison of ANA positivity





ANA positivity higher in
patients with chronic stable
angina; association with
severity of coronary stenotic
lesions
f death National Death
Registry
High titer of ANAs associated
with increased risk of death
tes Not mentioned ANA positivity higher in




















e and risk of death




Akmatov et al. Arthritis Research & Therapy  (2017) 19:127 Page 8 of 9strongly (≥1:1280) positive titers, respectively. These
individuals may be at higher risk of developing auto-
immune diseases.
Why did our study not detect any association between
ANA titer and/or pattern and the selected cardiovascu-
lar and metabolic variables? One reason may lie in the
inherent methodological differences from other studies
on the topic (summarized in Table 4). In contrast to those
studies, which used diagnoses from medical records and
were based on physical examinations, our analysis was
based in part on participants’ self-reported information
regarding diabetes and elevated blood cholesterol (see
Methods). However, the lack of associations between
ANAs and BMI or hypertension was determined based on
physical measurements obtained in the study centers. This
finding agrees with the lack of association with hyperten-
sion reported by Ishikawa et al. [25], but also suggests that
the association with BMI in women reported by Gonzalez
et al. [10] may not apply across populations.
We used the AKLIDES semi-automated system because
it would lend itself well to high-throughput ANA determi-
nations of large sample numbers typical of present-day
“mega cohorts” like the GNC. Hospital-based studies
showed that the AKLIDES system yields comparable
results to the gold standard (i.e., visual inspection and
evaluation by a clinical immunologist). For instance,
Bizzaro et al. [26] found that the diagnostic accuracy of
the AKLIDES system for automated ANA assessment was
very high (sensitivity, 97.8%). Melegari et al. [27] observed
very high agreement (98.9%) between automated and vis-
ual assessments of the AKLIDES system. Our study now
demonstrated the feasibility of also using the AKLIDES
system in a population-based analysis. Taken together, the
results support the use of this system in future large-scale
population-based studies that require the high-throughput
capability of this system.
Limitations of the present study include its cross-
sectional nature, which precludes causal inferences. Be-
cause the overall sample size was relatively small, it may
not have been sufficient to detect significant associations
between ANA positivity and the metabolic outcome var-
iables studied. Thus, further research examining these
relationships is required. It would have been important
to validate the clinical relevance of ANA positivity, in
particular of high titer, by testing for associations with
autoimmune disorders such as SLE or SjS. However, this
was not possible due to the very low numbers of self-
reported cases (SLE = 4; SjS = 7), which are consistent
with the low prevalences of these disorders in Germany
[28, 29]. We pooled data from two cross-sectional stud-
ies (i.e. pretests 1 and 2), which were conducted in 2011
and 2012. There were slight differences in the designs of
the questionnaires used in the pretest 1 and 2 studies
and in the methodology of the studies. For example,blood pressure was only measured once in the Essen
study center, while it was measured three times in the
other study centers. In terms of metabolic disorders the
questions did not differ. Further supporting our use of
the pooled data set, there were no differences in ANA
positivity between samples from pretest 1 vs. pretest 2.
Conclusions
The prevalence of ANA positivity in the German general
population was similar to values reported from other
countries. Contrary to other studies, there was no asso-
ciation between ANA positivity and self-reported and
objectively measured selected cardiovascular and meta-
bolic disorders.
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